• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [External evaluation of cancer care organization and delivery: review of experiences relevant to the cancer team evaluation and designation process in Québec]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2012     Andalusian Health Technology Assessment Area (AETSA) [Extended neonatal screening for lysosomal diseases by mass spectrometry]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extended adjuvant endocrine therapy in breast cancer]
2006     Andalusian Health Technology Assessment Area (AETSA) [Expulsion stage of delivery: comparison of upright versus lying down positions for childbirth, through maternal and foetal outcomes]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Exploratory evaluation of the relevance, use, and impacts of teleconsultations]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Surgery for varices" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Decompression for carpal tunnel syndrome" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Conization of the cervix uteri" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Cataract surgery" -Rapid report]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Expertise on endometriosis]
2020     National Committee for Technology Incorporation (CONITEC) [Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Expanding thrombolysis in acute ischemic stroke: organizing effective and efficient daily care in The Netherlands]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy in patients with peripheral arterial disease: the costs and effectiveness of physiotherapeutic supervision with or without therapy feedback versus a 'go home and walk' advice]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy for patellofemoral pain syndrome: a randomised clinical trial in general practice and sports medicine]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Exercise therapy (Krankengymnastik / Heilgymnastik) in physical medicine]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exenatide in diabetes mellitus type 2 - Rapid report]
2020     National Committee for Technology Incorporation (CONITEC) [Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Exantia® tissue bulking agent for the treatment of fecal incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Examination of barriers and facilitators for the implementation of clinical practice guidelines: a Delphi study]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Examination and treatment of older people after a fall – a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence-based patient information on chronic obstructive airway diseases - Asthma]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evidence overview of therapeutic hypothermia]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evidence brief on the measures related to the reimbursement of blood glucose test strips]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Everolimus (Afinitor) for the treatment of renal cell carcinoma]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of vascular care in Alzheimer's disease]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the utility and indication of prostate biopsies with image fusion – magnetic resonance and transrectal ultrasound]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
1998     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of the use of antidigoxin antibodies in the treatment of digitalis intoxication]
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the ultrasonic flowmeter for verification of graft patency during coronary artery bypass grafting]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the scientific evidence on nipple-areola complex micropigmentation, requirements for its proper implementation and costs]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of the potential of real-time 3-dimensional echocardiography in the assessment of right ventricular function in adult congenital heart disease: comparison of RT-3D echo with MRI]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal strategy for subsidizing pneumococcal vaccination in the elderly]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Canary Health Service [Evaluation of the lung cancer screening program]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the implementation of clinical guidelines in the Basque Country. Cluster randomized trial]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluation of the impact in inequality before and after the enhancement of health insurance coverage of cancer]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the efficacy and safety of negative pressure in the treatment of chronic wounds]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the effectiveness of psychological intervention in the first psychotic episode by multidisciplinary treatment]
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the effectiveness of hip and knee implant models used by the Spanish National Health System]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the effectiveness and cost effectiveness of cardiac rehabilitation programs]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Evaluation of the Danish National Cancer Action Plan - status and future monitoring - summary and proposals for focus areas]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Evaluation of the change in medical services before and after the enhancement of health insurance coverage of cancer]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the benefits and harms of statins (with particular consideration of atorvastatin)]
2016     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of technologies allowing the induction of therapeutic hypothermia in patients who have suffered a cardiac arrest]
2003     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of techniques for detecting breast implant rupture]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Evaluation of taking mifepristone at home during a medical abortion]
2011     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of surrogate variables in oncology. Advanced and metastatic breast cancer]